Introduction

Plantar fasciitis and associated bone formation, referred to as “plantar heel spur”, constitute a very common cause of plantar pain. Plettner, a German surgeon, was first to describe calcaneal spur in 1900 (1). Factors associated with plantar fasciitis include increased body weight, intensive workload and sportive activity and working on hard surfaces (2-4). Patient symptomatology typically includes stinging and severe heel pain with potential gait and mobility disturbances accompanied by worsened quality of life.

Several mechanisms are thought to play a role in the occurrence of pain from heel spur. Vertical compression leads to continual microtraumas and eventual degeneration of fascia at calcaneal insertion area, which is typically followed by inflammatory tissue reactions (5). Inflammation may result in thickening of the fascia along with exostotic bone formation as the heel spur. Staged development of heel spur has been described by Kumai and Benjamin (6). While patients with heel spur may typically suffer from severe pain, there may be cases without pain and also some patients with plantar fasciitis may present with pain albeit without radiographic evidence of heel spur formation. Diagnosis is based on history and physical examination findings with typical localization of pain (7). While sophisticated imaging techniques including ultrasonography or magnetic resonance imaging are not routinely utilized, radiographs may be used for showing heel spurs and facilitates

© Murat Beyzadeoğlu, Ömer Sağır, Ferrat Dinçoğlan, Selçuk Demiral, Bora Uysal, Hakan Gamsız, Fatih Özcan, Onurhan Çolak, Bahar Dirican

University of Health Sciences Turkey, Gülhane Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey

Evaluation of the radiotherapeutic management of refractory painful heel spur and plantar fasciitis: a single center experience of 45 years

Aim: Heel spur is exostosis of the calcaneus. Plantar fasciitis and heel spur constitute a very common cause of plantar pain, which may be managed with radiation therapy (RT). In this study, we assessed the radiotherapeutic management of refractory painful heel spur and plantar fasciitis.

Methods: In this retrospective study, we report our single center experience with RT for refractory painful heel spur and plantar fasciitis management over a period of 45 years and describe patient and treatment characteristics.

Results: Between 1974 and 2019, a total of 4904 patients received RT at our department using cobalt-60 teletherapy machine for the management of refractory painful heel spur and plantar fasciitis. Out of the total 4904 patients, 2012 patients (41%) were male and 2892 patients (59%) were female. The median age was 51 (range: 41-85) years. All patients had received previous therapies for refractory painful heel spur and plantar fasciitis before the management with RT. Total RT dose was 8 Gy delivered in 2 consecutive days with daily fractions of 4 Gy using 2 opposing anterior-posterior RT fields to both heels without bolus material. Treatment response was assessed 3 to 5 weeks after the completion of RT. Response to RT was complete in 3579 patients (73%), partial in 1188 patients (24.2%), and none in 137 patients (2.8%). No therapy-related toxicity was observed in the whole series.

Conclusion: RT for refractory painful heel spur and plantar fasciitis may offer effective palliation of pain and may be considered as a viable therapeutic option for selected patients exhausted with other treatment modalities.

© Copyright 2020 by the University of Health Sciences Turkey, Gülhane Faculty of Medicine / Gülhane Medical Journal published by Galenos Publishing House.
the exclusion of other diseases such as metastatic involvement of the bone.

Over a decade after its first description, several therapeutic modalities have been used for the management of painful heel spur and plantar fasciitis. Modification of life style to prioritize resting, losing weight and avoiding from intensive physical workload, analgesics, cold compresses, iontophoresis, antiinflammatory agent and steroid injections, stretching exercises and physical therapy, laser, microwave, ultrasound therapy, orthotics and shoe modifications, foot orthoses and insoles, heel pads, efforts to decrease pressure on the affected site, orthopedic interventions, and radiation therapy (RT) are among the methods for eradicating or alleviating pain from heel spur and plantar fasciitis (8-10). The use of foot orthoses and insoles may result in functional improvement and reduction of pain from plantar fasciitis and heel spurs (9,10).

RT has a long history in the management of painful heel spur and plantar fasciitis. Accumulated data from several centers have consistently reported effective palliation of painful plantar fasciitis and heel spur; however, dose fractionation schemes and treatment fields may vary among the institutions and are typically based on retrospective data and experiences (2,11-26).

In this study, we report our single center experience with RT for painful heel spur and plantar fasciitis management over a period of 45 years and describe patient and treatment characteristics including RT dose, fractionation, target volume, and pain response.

**Methods**

This retrospective study was conducted in accordance with the Code of Ethics of the World Medical Association, Declaration of Helsinki principles, and Uniform Requirements for manuscripts submitted to medical journals with the approval of Gülhane Faculty of Medicine, Radiation Oncology Department (date: 07.02.2020).

Informed consents of all patients were taken before RT.

A total of 4904 patients with painful heel spur and plantar fasciitis were treated at our institution over a period of 45 years between 1974 and 2019. All patients were referred for refractory painful heel spur and plantar fasciitis and had received previous medications including analgesics, cold compresses, iontophoresis, antiinflammatory agent and steroid injections, stretching exercises and physical therapy, laser, microwave, ultrasound therapy, orthotics and shoe modifications, heel pads, efforts to decrease pressure on the affected site and orthopedic interventions before RT. If available, imaging data of the patients were assessed for precise localization of plantar heel spur as shown in Figure 1.

Patient and treatment characteristics such as age, gender, RT dose and fractionation, toxicity and response to treatment were analyzed. Response to RT was stratified as no response, partial response, and complete response. Patients were simulated at X-ray 2D (dimensional) simulator available at our department. After 2D simulation for the designation of treatment portals and marking of the treatment fields on the patients’ heels with permanent markers, setup of the patients was performed at cobalt-60 (Co-60) teletherapy unit with both soles apposing as shown on Figure 2. Total RT dose was 8 Gy delivered in 2 fractions using 2 opposing anterior-posterior (AP/PA) RT fields to both heels without bolus material (Figure 2). Treatment response was assessed 3 to 5 weeks after the completion of RT.

**Statistical Analysis**

Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL) software (version 15.0) was used for analysis.
Descriptive statistics were used for the description of basic features of data in our study.

**Results**

Between 1974 and 2019, 4904 patients received RT for the management of refractory painful heel spur and plantar fasciitis. All patients were treated at our department using Co-60 teletherapy machine for refractory painful plantar fasciitis or heel spur. Patient characteristics, treatment characteristics and response are shown on Table 1 and Table 2, respectively.

Out of the total 4904 patients, 2012 patients (41%) were male and 2892 patients (59%) were female. The median age was 51 (range: 41-85) years. All patients had received previous therapies for painful plantar fasciitis or heel spur before RT. Total RT dose was 8 Gy delivered in 2 consecutive days with daily fractions of 4 Gy using 2 opposing AP/PA RT fields to both heels without bolus material. Treatment response was assessed 3 to 5 weeks after the completion of RT. Treatment response was complete in 3579 patients (73%), partial in 1188 patients (24.2%), and none in 137 patients (2.8%). No therapy-related toxicity was observed in the whole series.

**Discussion**

Our study comprises a large series of patients treated over a long period of 45 years at a tertiary referral institution. Our single center experience confirms the efficacy of RT with Co-60 teletherapy machine for the management of refractory painful heel spur and plantar fasciitis.

Plantar heel spur has been defined as an exostotic bone formation localized at the insertion site of plantar fascia (1,12). While there is no established preponderance for gender in the literature, our series of 4904 total patients included more female patients than male patients. Typical age of presentation is over 40 years, which is consistent with our study population having a median age of 51 (range: 41-85) years. Affected patients may suffer from stinging and severe heel pain with potential gait and mobility disturbances accompanied by worsened quality of life. Repetitive microtraumas with resultant damage of the plantar aponeurosis and muscle insertions by excessive stress on the heels may have role in pathogenesis (27). Increased straining may stem from intensive sport activities, foot deformities, increased body weight, and working on hard surfaces (2-4,12,27-29). A plethora of treatments have been used for the management including modification of life style to prioritize resting, losing weight and avoiding from intensive physical workload, analgesics, cold compresses, iontophoresis, antiinflammatory agent and steroid injections, stretching exercises and physical therapy, laser, microwave, ultrasound therapy, orthotics and shoe modifications, heel pads, efforts to decrease pressure on the affected site, orthopedic interventions, and RT.

Traditionally, RT has been reserved for refractory cases due to concerns about adverse radiation effects such as carcinogenesis (15). While several countries in Europe have adopted RT for the management of several benign conditions including musculoskeletal, degenerative, and inflammatory disorders with encouraging treatment outcomes, the use of RT for nonmalignant benign conditions have been considered skeptical as well by several centers (15,30-34). Besides its utility in the management of several cancers throughout the whole human body, ionizing radiation may induce mutations and carcinogenesis. However, no carcinogenesis was reported in our series, and decision making for management with RT should be individualized based on a harm to benefit ratio (35). Mechanism of action for RT has been extensively studied, and may be possibly through modulating the intensity of inflammation along with possible neurolysis of the sural and posterior tibial nerves.

**Table 1. Patient characteristics**

| Patient characteristic | Number | % |
|-----------------------------|--------|---|
| Number of patients          | 4904   | 100 |
| Male                        | 2012   | 41 |
| Female                      | 2892   | 59 |
| Median age (range)          | 51 (41-85) years | 100 |
| Diagnosis                   |        |    |
| Painful plantar fasciitis/heel spur | 4904 | 100 |
| Use of previous therapies   | 4904   | 100 |

**Table 2. Treatment characteristics and response**

| Indication for RT              | Number | % |
|--------------------------------|--------|---|
| Refractory painful plantar fasciitis/heel spur | 4904 patients | 100 |
| RT dose per fraction           | 4 Gy   | 100 |
| Total number of RT fractions   | 2      | 100 |
| Total RT dose                  | 8 Gy   | 100 |
| Treatment length               | 2 consecutive days | 100 |
| Treatment modality             |        |    |
| EBRT                           | 4904 patients | 100 |
| Treatment machine              |        |    |
| Co-60                          | 4904 patients | 100 |
| RT technique                   |        |    |
| Two opposing AP/PA RT fields including bilateral heels | 4904 patients | 100 |
| Time period for treatment response assessment | 4904 patients | 100 |
| 3 to 5 weeks after completion of RT   |        |    |
| Treatment response             |        |    |
| Complete response              | 3579 patients | 73 |
| Partial response               | 1188 patients | 24.2 |
| No response                    | 137 patients | 2.8 |

RT: Radiation therapy, EBRT: External beam radiation therapy, AP/PA: Anterior-posterior, Co-60: Cobalt-60
Several trials have been conducted to assess the utility of low dose irradiation in the management of heel spur and plantar fasciitis (11-26). While the exact mechanism of pain relief by irradiation is an area of research, RT may also induce a placebo effect in some patients (24). In terms of dose and fractionation, there is no standard fractionation scheme for the irradiation of painful heel spur and plantar fasciitis. Several dose-fractionation schemes have been evaluated, and total delivered doses in the range of 3 to 12 Gy have been found to be effective (24). In the study by Seegenschmiedt et al. (11), 3 dose-fractionation schemes were comparatively assessed, and 10x0.5 Gy to a total dose of 5 Gy was reported to be superior than 10x0.3 Gy to a total dose of 3 Gy and 12x1 Gy to a total dose of 12 Gy in terms of pain relief. In the retrospective study by Mücke et al. (12) assessing low dose irradiation for the management of painful heel spur in 117 patients, over 80% of the patients benefited from RT. The authors suggested commencing RT within 6 months of symptom onset to achieve effective pain palliation (12). Micke et al. (13) reported the results of a national patterns of care study from Germany. The study included a very high number of cases treated with RT for painful heel spur syndrome in several centers of Germany, and confirmed the safety and efficacy of irradiation for this indication (13). Complete relief of pain over 3 months has been achieved in median 70% (range: 25%-100%) of all treated patients (13). Persisting pain relief for at least 1 year has been reported in median 65% (range: 19%-99%) of the patients (13). The median percentage of patients without symptomatic improvement was 15% (range: 5%-50%), and no toxicity or secondary cancers have been reported during the follow-up period (13). Vast majority of radiation oncologists participating in the national survey has considered RT as a viable and essential treatment indication for painful heel spur syndrome (13). Schwarz et al. (14) assessed the use of single fraction RT for heel spur and plantar fasciitis, and concluded that irradiation with single fraction might be further investigated in future trials. Heyd et al. (16) prospectively evaluated 130 patients in a randomized study and found comparable results with both fractionation schemes of 6x0.5 Gy and 6x1 Gy. In a study by Niewald et al. (19), two fractionation schemes of 6x1 Gy and 6x0.1 Gy were comparatively assessed, and a total dose of 6 Gy delivered in 6 fractions of 1 Gy each was found to achieve superior pain relief than 6x0.1 Gy. Hermann et al. (20) assessed the effect of field size and plantar spur length on the outcome of RT for plantar fasciitis management. They reported that patients with short heel spurs benefited from RT equally as patients with no radiological evidence of spur (20). Also, they reported that the use of smaller field sizes was also effective and could be used for minimizing exposure of normal tissues (20). Koca et al. (21) reported the results of 62 patients treated using a Co-60 teletherapy machine. Their series of 62 patients included 53 female and 9 male patients with female preponderance consistent with our series (21). With a total dose of 8 Gy, response to RT was reported to be no response in 21%, partial response in 21%, and complete response in 58% of the total 62 patients (21).

Although irradiation for painful heel spur and plantar fasciitis has been considered as a last resort treatment traditionally, there is accumulating data supporting the utility of RT for the management of pain from heel spur and plantar fasciitis (2,11-26). Our study adds to the literature with high number of patients treated using a standard treatment machine and uniform dose-fractionation scheme at a single institution over 45 years. Since our results reveal satisfactory pain relief by the use of RT without treatment-related toxicity and secondary malignancies in accordance with the literature, we conclude that RT is safe and effective for the management of refractory painful heel spur and plantar fasciitis management. Clearly, comparative evaluation of different modalities for this indication in future studies may shed light on optimal decision making for the management of patients with painful heel spur and plantar fasciitis.

**Conclusion**

Our single center experience confirms the efficacy of RT for the management of refractory painful heel spur and plantar fasciitis. RT offers a non-invasive treatment modality and should be considered as a viable therapeutic option for this indication. Without downsizing of the spur, RT achieves effective pain relief which is a major cause of deterioration in quality of life. Future studies are warranted to assess the comparative efficacy of different modalities in the management of painful heel spur and plantar fasciitis.

**Ethics**

**Ethics Committee Approval:** This retrospective study was conducted in accordance with the Code of Ethics of the World Medical Association, Declaration of Helsinki principles, and Uniform Requirements for manuscripts submitted to medical journals with the approval of Gülhane Faculty of Medicine, Radiation Oncology Department (date: 07.02.2020).

**Informed Consent:** Informed consents of all patients were taken.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Concept: M.B., Ö.S., S.D., H.G., F.Ö., B.D., Design: Ö.S., F.D., S.D., H.G., F.Ö., B.D., Data Collection or Processing: M.B., Ö.S., F.D., S.D., B.U., H.G., F.Ö., O.Ç., B.D., Analysis or Interpretation: M.B., Ö.S., S.D., B.U., H.G., O.Ç., B.D., Literature
Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Plettner P. Exostosen des Fersenbeins. Dresden: Jahresber Ges Natur Heilkunde; 1900.
2. Hermann MR, Bruns F, Nitsche M. Low-Dose Radiotherapy of Painful Heel Spur/Plantar Fasciitis as an Example of Treatment Effects in Benign Diseases. Radiotherapy, In: Cem Onal ed. IntechOpen; 2017.
3. Sahin N, Oztürk A, Atıcı T. Foot mobility and plantar fascia elasticity in patients with plantar fasciitis. Acta Orthop Traumatol Turc. 2010;44:385-391.
4. Irving DB, Cook JL, Young MA, Menz HB. Obesity and pronated foot type may increase the risk of chronic plantar heel pain: a matched case-control study. BMC Musculoskelet Disord. 2007;8:41.
5. Menz HB, Zammit GV, Landorf KB, Munteanu SE. Plantar fascia: to treat or not to treat? J Foot Ankle Surg. 2018;57:370-381.
6. Kumai T, Benjamin M. Heel spur formation and the subcalcaneal enthesis of the plantar fascia. J Rheumatol. 2002;29:1957-1964.
7. Schneider HP, Baca JM, Carpenter BB, Dayton PD, Fleischer AE, Sachs BD. American College of Foot and Ankle Surgeons Clinical Consensus Statement: Diagnosis and Treatment of Adult Acquired Infracalcaneal Heel Pain. J Foot Ankle Surg. 2018;57:370-381.
8. Beyzadeoglu M, Ozyigit G, Seleik U. Rare Tumors and Benign Diseases (Chapter 15). In: Radiation Oncology: Treatment Effects in Benign Diseases. Radiotherapy, In: Cem Onal ed. IntechOpen; 2017.
9. Bevacechi A, Delank KS. Pain on the Plantar Surface of the Foot. Dtsch Arztebl Int. 2019;116:83-88.
10. Lee SY, McKeon P, Hertel J. Does the use of orthoses improve self-reported pain and function measures in patients with plantar fasciitis? A meta-analysis. Phys Ther Sport. 2009;10:12-18.
11. Seegenschmiedt MH, Keilholz L, Katalinic A, Stecken A, Sauer R. Heel spur: radiation therapy for refractory pain--results with three treatment concepts. Radiology. 1996;200:271-276.
12. Mücke R, Schönekaes K, Micke O, Seegenschmiedt MH, Berning D, Heyder R. Low-dose radiotherapy for painful heel spur: Retrospective study of 117 patients. Strahlenther Onkol. 2003;179:774-778.
13. Micke O, Seegenschmiedt MH; German Cooperative Group on Radiotherapy for Benign Diseases. Radiotherapy in painful heel spurs (plantar fasciitis)--results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2004;58:828-843.
14. Schwarz F, Christie DR, Irving M. Are single fractions of radiotherapy suitable for plantar fasciitis? Australas Radiol. 2004;48:162-169.
15. Surenkok S, Dirican B, Beyzadeoglu M, Oysul K. Heel spur radiotherapy and radiation carcinogenesis risk estimation. Radiat Med. 2006;24:573-576.
16. Heyd R, Tselis N, Ackermann H, Röddiger SJ, Zamboglou N. Radiation therapy for painful heel spurs: results of a prospective randomized study. Strahlenther Onkol. 2007;183:3-9.
17. Mischczyn L, Jochymek B, Wozniak G. Retrospective evaluation of radiotherapy in plantar fasciitis. Br J Radiol. 2007;80:829-834.
18. Muecke R, Micke O, Reichl B, et al. Demographic, clinical and treatment related predictors for event-free probability following low-dose radiotherapy for painful heel spurs - a retrospective multicenter study of 502 patients. Acta Oncol. 2007;46:239-246.
19. Niewald M, Seegenschmiedt MH, Micke O, et al. Randomized, multicenter trial on the effect of radiotherapy on plantar fasciitis (painful heel spur) comparing a standard dose with a very low dose: mature results after 12 months' follow-up. Int J Radiat Oncol Biol Phys. 2012;84:e455-462.
20. Hermann RM, Meyer A, Becker A, et al. Effect of field size and length of plantar spur on treatment outcome in radiation therapy of plantarfasciitis: the bigger the better? Int J Radiat Oncol Biol Phys. 2013;87:1122-1128.
21. Koca T, Aydin A, Sezen D, Başaran H, Karaca S. Painful plantar heel spur treatment with Co-60 teletherapy: factors influencing treatment outcome. Springerplus. 2014;3:21.
22. Hautmann MG, Neumaier U, Kübbi O. Re-irradiation for painful heel spur syndrome. Retrospective analysis of 101 heels. Strahlenther Onkol. 2014;190:298-303.
23. Uysal B, Beyzadeoglu M, Sager O, et al. Role of radiotherapy in the management of heel spur. Eur J Orthop Surg Traumatol. 2015;25:387-389.
24. Holtmann H, Niewald M, Prokein B, Graeber S, Ruebe C. Randomized multicenter follow-up trial on the effect of radiotherapy for plantar fasciitis (painful heels spur) depending on dose and fractionation - a study protocol. Radiat Oncol. 2015;10:23.
25. Niewald M, Holtmann H, Prokein B, et al. Randomized multicenter follow-up trial on the effect of radiotherapy on painful heel spur (plantar fasciitis) comparing two fractionation schedules with uniform total dose: first results after three months' follow-up. Radiat Oncol. 2015;10:174.
26. Prokein B, Holtmann H, Hautmann MG, et al. Radiotherapy of painful heel spur with two fractionation regimens: Results of a randomized multicenter trial after 48 weeks' follow-up. Strahlenther Onkol. 2017;193:483-490.
27. Wearing SC, Smeathers JE, Urry SR, Hennig EM, Hills AP. The pathomechanics of plantar fasciitis. Sports Med. 2006;36:585-611.

28. Yi TI, Lee GE, Seo IS, Huh WS, Yoon TH, Kim BR. Clinical characteristics of the causes of plantar heel pain. Ann Rehabil Med. 2011;35:507-513.

29. Prichasuk S, Subhadrabandhu T. The relationship of pes planus and calcaneal spur to plantar heel pain. Clin Orthop Relat Res. 1994;306:192-196.

30. Ott OJ, Niewald M, Weitmann HD, et al. DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: Painful degenerative skeletal disorders. Strahlenther Onkol. 2015;191:1-6.

31. Trott KR. Therapeutic effects of low radiation doses. Strahlenther Onkol. 1994;170:1-12.

32. Schneider O, Stückle CA, Bosch E, Gott C, Adamietz IA. Effectiveness and prognostic factors of radiotherapy for painful plantar heel spurs. Strahlenther Onkol. 2004;180:502-509.

33. Minten MJ, Mahler E, den Broeder AA, Leer JW, van den Ende CH. The efficacy and safety of low-dose radiotherapy on pain and functioning in patients with osteoarthritis: a systematic review. Rheumatol Int. 2016;36:133-142.

34. Cannon B, Randolph JG, Murray JE. Malignant irradiation for benign conditions. N Engl J Med. 1959;260:197-202.

35. Hall EJ. Kaplan Distinguished Scientist Award 2003. The crooked shall be made straight; dose-response relationships for carcinogenesis. Int J Radiat Biol. 2004;80:327-337.

36. Hildebrandt G, Jahns J, Hindemith M, et al. Effects of low dose radiation therapy on adjuvant induced arthritis in rats. Int J Radiat Biol. 2000;76:1143-1153.

37. Mononuclear cell adhesion and cell adhesion molecule liberation after X-irradiation of activated endothelial cells in vitro. Int J Radiat Biol. 2002;78:315-325.

38. Roedel F, Kley N, Beuscher HU, et al. Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. Int J Radiat Biol. 2002;78:711-719.